Table 1.

Knowledge gaps.

In situ T. cruzi metabolic adaptations to infecting different tissues

Role of microbiota metabolism in CD pathogenesis

Role of metabolic adaptations in uninfected but infection-adjacent cells in CD pathogenesis

Relationship between metabolic resilience and CD symptom localization, across clinical T. cruzi isolates

Cross-talk between immune system, localized metabolic perturbations, and CD tropism

Translatability of altered metabolic pathways into new CD treatments

Translatability of altered metabolic pathways into biomarkers of CD progression or treatment success

Role of the local metabolic environment in treatment failure